Shots:
AI is moving drug development from computation to clinical confidence, showing how it now guides target discovery, molecule design, patient stratification, and trial planning while turning fragmented biomedical data into decision-ready insight that reduces risk, cost, and failure rates.
Trust, transparency, and regulation define AI’s real breakthrough, as the focus shifts beyond speed toward…
Shots:Â Â
Lilly leads with precision and purpose with 45 deals totaling $21.22B in 2025, focusing on platform-driven, science-led partnerships across oncology, gene therapy, RNA editing, and AI-enabled discovery while building durable innovation engines rather than chasing short-term winsÂ
Strategic dealmaking over sheer volume is evident in partnerships like precision oncology with Scorpion Therapeutics and CNS delivery with Sangamo, structured to…

